01 1Epzicom
02 6Epzicom/Kivexa
03 10Triumeq
04 3Trizivir
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 43
2019 Revenue in Millions : 104
Growth (%) : -59
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 3,197
2019 Revenue in Millions : 3,534
Growth (%) : -10
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 2,547
2020 Revenue in Millions : 3,159
Growth (%) : -18
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2022 Revenue in Millions : 2,218
2021 Revenue in Millions : 2,547
Growth (%) : -13
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2023 Revenue in Millions : 1,664
2022 Revenue in Millions : 2,218
Growth (%) : -14
Abacavir, Dolutegravir, Lamivudine
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2024 Revenue in Millions : 1,648
2023 Revenue in Millions : 1,664
Growth (%) : -1
Main Therapeutic Indication : Infectious Diseases (HIV, Hepatitis...
Currency : USD
2015 Revenue in Millions : 1,091
2014 Revenue in Millions : 991
Growth (%) : -9%
Abacavir, Dolutegravir, Lamivudine
Main Therapeutic Indication : Infectious Diseases (HIV, Hepatitis...
Currency : USD
2015 Revenue in Millions : 0
2014 Revenue in Millions : 1,037
Growth (%) : New Launch
Abacavir, Lamivudine, Zidovudine
Main Therapeutic Indication : Infectious Diseases (HIV, Hepatitis...
Currency : USD
2015 Revenue in Millions : 51
2014 Revenue in Millions : 37
Growth (%) : -27%
Main Therapeutic Indication : Infectious Diseases (HIV, Hepatitis...
Currency : USD
2014 Revenue in Millions : 0.70%
2013 Revenue in Millions :
Growth (%) :
